[PBBANK] QoQ Annualized Quarter Result on 30-Sep-2017 [#3]

Announcement Date
26-Oct-2017
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2017
Quarter
30-Sep-2017 [#3]
Profit Trend
QoQ- 2.97%
YoY- 6.99%
View:
Show?
Annualized Quarter Result
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Revenue 21,570,182 21,396,612 20,858,174 20,676,832 20,390,664 20,112,740 20,102,740 4.82%
PBT 7,103,370 7,175,836 7,117,672 6,880,580 6,734,962 6,525,888 6,554,032 5.52%
Tax -1,426,788 -1,484,720 -1,570,693 -1,491,761 -1,500,274 -1,464,516 -1,286,597 7.15%
NP 5,676,582 5,691,116 5,546,979 5,388,818 5,234,688 5,061,372 5,267,435 5.12%
-
NP to SH 5,603,200 5,621,520 5,470,035 5,312,756 5,159,614 4,991,924 5,206,875 5.02%
-
Tax Rate 20.09% 20.69% 22.07% 21.68% 22.28% 22.44% 19.63% -
Total Cost 15,893,600 15,705,496 15,311,195 15,288,013 15,155,976 15,051,368 14,835,305 4.71%
-
Net Worth 39,318,987 37,614,813 37,364,587 35,908,418 35,524,587 34,196,617 34,213,222 9.74%
Dividend
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Div 2,472,916 - 2,355,511 1,390,137 2,085,206 - 2,239,666 6.84%
Div Payout % 44.13% - 43.06% 26.17% 40.41% - 43.01% -
Equity
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Net Worth 39,318,987 37,614,813 37,364,587 35,908,418 35,524,587 34,196,617 34,213,222 9.74%
NOSH 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 0.00%
Ratio Analysis
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
NP Margin 26.32% 26.60% 26.59% 26.06% 25.67% 25.17% 26.20% -
ROE 14.25% 14.94% 14.64% 14.80% 14.52% 14.60% 15.22% -
Per Share
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
RPS 558.24 554.10 540.16 535.46 528.05 520.85 520.59 4.77%
EPS 145.06 145.56 141.66 137.59 133.62 129.28 134.84 5.00%
DPS 64.00 0.00 61.00 36.00 54.00 0.00 58.00 6.80%
NAPS 10.1759 9.741 9.6762 9.2991 9.1997 8.8558 8.8601 9.69%
Adjusted Per Share Value based on latest NOSH - 3,882,138
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
RPS 111.13 110.23 107.46 106.52 105.05 103.62 103.57 4.82%
EPS 28.87 28.96 28.18 27.37 26.58 25.72 26.82 5.04%
DPS 12.74 0.00 12.14 7.16 10.74 0.00 11.54 6.83%
NAPS 2.0256 1.9378 1.9249 1.8499 1.8302 1.7617 1.7626 9.74%
Price Multiplier on Financial Quarter End Date
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Date 29/06/18 30/03/18 29/12/17 29/09/17 30/06/17 31/03/17 30/12/16 -
Price 23.36 24.00 20.78 20.44 20.32 19.90 19.72 -
P/RPS 4.18 4.33 3.85 3.82 3.85 3.82 3.79 6.76%
P/EPS 16.11 16.49 14.67 14.86 15.21 15.39 14.62 6.70%
EY 6.21 6.07 6.82 6.73 6.58 6.50 6.84 -6.25%
DY 2.74 0.00 2.94 1.76 2.66 0.00 2.94 -4.60%
P/NAPS 2.30 2.46 2.15 2.20 2.21 2.25 2.23 2.08%
Price Multiplier on Announcement Date
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Date 15/08/18 02/05/18 22/02/18 26/10/17 25/07/17 20/04/17 02/02/17 -
Price 24.48 23.78 22.28 20.48 20.42 19.92 20.14 -
P/RPS 4.39 4.29 4.12 3.82 3.87 3.82 3.87 8.79%
P/EPS 16.88 16.33 15.73 14.89 15.28 15.41 14.94 8.50%
EY 5.92 6.12 6.36 6.72 6.54 6.49 6.70 -7.94%
DY 2.61 0.00 2.74 1.76 2.64 0.00 2.88 -6.36%
P/NAPS 2.41 2.44 2.30 2.20 2.22 2.25 2.27 4.08%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment